Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing
NA
Historically, serial testing of patients with metastatic breast cancer has ...
A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)
N/A
This disease registry is a prospective, multicenter non-interventional stud...
Status
Completed
Location
Lkh-Univ. Klinikum Graz; Klinik Für Gynäkologie
Start Date
2016-11-16
Trial ID
NCT02913456
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
PHASE2
Study to evaluate the safety, tolerability, antitumor activity, and pharmac...
A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
N/A
This disease registry is a prospective, multicenter non-interventional stud...